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Abstract  
Purpose 
The CHHiP trial investigated the use of moderate hypofractionation for treatment of localised 
prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance 
(QA) programme was developed to assess compliance with treatment protocol and audit treatment 
planning and dosimetry of IMRT. This paper considers the outcome and effectiveness of the 
programme. 
Methods and Materials 
QA exercises included a pre-trial process document and planning benchmark cases, prospective case 
reviews and a dosimetry site visit on- trial, and a post-trial feedback questionnaire. 
Results 
41 centres completed the QA programme (37 UK, 4 international) between 2005 and 2010. Centres 
used either forward-planned (field-in-field single phase) or inverse-planned IMRT (25 vs 17).  
For pre-trial QA exercises, 7/41 (17%) centres had minor deviations in their radiotherapy processes; 
45/82 (55%) benchmark plans had minor variations and 17/82 (21%) major variations. 
100 prospective case reviews were completed for 38 centres. 71% required changes to clinical 
outlining pre-treatment (primarily prostate apex and base, seminal vesicles, and penile bulb). Errors 
in treatment planning were reduced relative to pre-trial QA results (49% minor and 6% major 
variations). 
Dosimetry audits were conducted for 32 centres. Ion chamber dose point measurements were 
within ±2.5% in the PTV and ±8% in the rectum. 28/36 films for combined fields passed gamma 
criterion 3%/3mm and 11/15 of IMRT fluence film sets passed gamma criterion 4%/4mm using a 98% 
tolerance. 
Post-trial feedback demonstrated that trial participation was beneficial in evolving clinical practice, 
and the QA programme helped some centres implement and audit prostate IMRT. 
Conclusion 
Overall, QA results were satisfactory and the CHHIP QA programme contributed to the success of the 
trial by auditing radiotherapy treatment planning and protocol compliance. QA supported the 
introduction of IMRT in UK centres, giving additional confidence and external review of IMRT where 
it was a newly adopted technique. 
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Introduction 
CHHiP (CRUK/06/016; ISRCTN97182923) is a randomised phase 3 multicentre trial of Conventional or 
Hypofractionated High Dose Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer (T1b–T3a 
N0 M0). The conventional arm used a dose schedule of 74Gy in 2Gy fractions (fr) and the 
hypofractionated groups used 60Gy/20fr and 57Gy/19fr. From October 2002 to June 2011, 3216 
men were recruited from 41 radiotherapy centres. The five year outcome data have been reported 
[1] and 60Gy/20fr has been recommended as the new standard of care by NHS England for external 
beam radiotherapy of localised prostate cancer. 
As IMRT was a novel technique in the UK at the time of trial inception a comprehensive quality 
assurance (QA) programme was developed, based on the UK RT01 [2] and PARSPORT [3] trial QA 
programmes but focussed more on prospective review. The programme was essential to ensure the 
technical and dosimetric quality of treatment delivered, evidence of compliance with the 
radiotherapy treatment protocol, and consistency between radiotherapy centres. All UK NIHR 
(National Institute of Health) Clinical Research Network radiotherapy clinical trials have QA 
programmes included from their inception. 
 
Methods 
Radiotherapy Protocol 
Clinical demographics of the trial population have been previously reported [1]. Patients were 
imaged and treated with a comfortably full bladder (>150ml) and empty rectum. Patients were 
treated supine using the centres’ standard immobilisation technique. 
Treatment was planned and delivered using a simultaneous integrated boost (SIB) technique with 
target volumes illustrated in Figure 1. Doses were prescribed following the recommendations of 
ICRU Report 62 [5].  
Radiotherapy treatment planning was performed using forward (fp-IMRT) or inverse (ip-IMRT) three-
dimensional methods. The complex forward-planned multi-segment SIB technique has been 
previously described [6]. Mandatory dose constraints were defined for planning target volumes 
(PTV) and organs at risk (OAR) (Appendix A), and reported for every trial patient using a standard 
Plan Assessment Form (PAF). Radiotherapy treatment and delivery procedures were identical for all 
trial arms within a centre. Portal imaging was used to verify treatment setup accuracy with a 
maximum 3mm tolerance, and use of image-guided techniques was encouraged.   
Quality Assurance Programme 
Completion and approval of all QA exercises was a pre-requisite for a centre commencing trial 
recruitment. The comprehensive QA programme evaluated the following elements of radiotherapy 
treatment: local radiotherapy treatment and delivery procedures (using a process document), 
clinical outlining, treatment planning, and accuracy of radiotherapy dosimetry. Results were 
categorised as ‘no variation’, ‘minor variation’ (deviation from protocol or optimal practice but 
unlikely to affect clinical outcome) and ‘major variation’ (unacceptable deviation with potential to 
influence clinical outcome). 
Planning benchmark case 
CT images with clinical target volumes and OARs pre-outlined were provided for two prostate 
patients (one low risk of seminal vesicle (SV) involvement [4] and one moderate SV risk case) for pre-
trial planning benchmark cases. Centres were instructed to grow the PTVs and prepare treatment 
plans in accordance with the CHHiP trial protocol for the 74Gy and 60Gy arms respectively. Plans 
were reviewed by the trial radiotherapy QA (RTQA) physicist using VODCA v4.4.2d software (MSS 
Medical Software Solutions GmbH). Plans were assessed for compliance with ICRU Report 83 [7], 
specifically checking conformance of isodoses to PTVs, minimising dose to critical organs, hot- and 
cold-spots, dose constraints achieved, and suitable beam configuration. 
Prospective case reviews 
Prospective case reviews of clinical outlining, by the Chief Investigator (CI), and treatment planning, 
by the RTQA physicist, were performed for the first two patients recruited per centre. An additional 
moderate risk case was reviewed if the first two patients were low risk, and extra reviews were 
requested if significant errors persisted. The Principal Investigator (PI) for each site was centrally 
reviewed and was responsible for internal accreditation of outlining for any additional co-
investigators at their centre.  
Dosimetry Site Visit 
A dosimetry site visit was conducted during the course of the trial. Centres were instructed to 
prepare a CHHiP treatment plan (74Gy/37fr) on a pre-outlined CT dataset of the CIRS pelvic semi-
anthropomorphic phantom (Figure 2). Additional measurements were performed if multiple 
planning techniques or treatment delivery equipment were used. 
Point dose measurements 
Dose for a single 2Gy fraction was measured using a PTW SemiFlex 0.125cm3 ion chamber at two 
measurement locations (in the PTV near the isocentre and in the rectum (Figure 2a)) and compared 
to the centres’ treatment planning system (TPS) calculated dose. Relative dose was measured, 
normalised to the measured standard output for a 10cmx10cm field. Results were evaluated for 
total dose and dose per field.  
Planar film measurements 
An axial 2D dose distribution through the PTV was measured in the CIRS pelvic phantom using Kodak 
EDR2 film (Figure 2b). Single field film measurements (fluence maps) were performed for ip-IMRT 
plans at a depth of 10cm in a 15cmx15cmx20cm solid water phantom with the gantry set to 0° using 
Kodak XV film. 
Films were analysed using the OmniPro™ I’mRT software using relative dosimetry (normalised to a 
value of 100% in a region of high dose and low dose gradient). Gamma analysis [8] was performed 
using 4% dose/4mm distance to agreement and 3%/3mm gamma criteria with a 10% dose threshold. 
Results were recorded as the percentage of pixels with γ<1. 
Results were evaluated using literature-derived criteria (Table 1). No hard pass/fail criteria were set. 
Feedback questionnaire 
A questionnaire was sent to all participating centres four months after the trial closed to 
recruitment.  This sought views on the impact of undertaking the CHHiP trial at the centre and 
requested feedback on the QA process. 
 
Results 
The QA exercises were completed by all 41 participating centres between December 2004 and 
March 2010. The average time taken to complete QA was 14 months (range 3-32 months). 
Equipment 
27 centres used Varian linear accelerators, 16 Elekta and 3 Siemens. Photon beams had a nominal 
energy in the range 6-25MV; most centres used 6MV or 10MV, with 6MV used preferentially for ip-
IMRT and 10MV for fp-IMRT. 
7 different TPSs were used: Eclipse (15 centres), Pinnacle (8), Oncentra MasterPlan (8), CMS XiO (7), 
Plato (3), TMS Helax (1), ARPS (1). 17 centres used ip-IMRT, 25 used fp-IMRT (1 centre used both), 
and 3 centres changed from fp-IMRT to ip-IMRT during the course of the trial. Ip-IMRT employed 
step and shoot or dynamic multi-leaf collimator delivery with 5 fields, and 1 centre used rotational 
radiotherapy. 
Treatment verification was primarily performed using electronic portal imaging, comparing MV 
images of bony anatomy with simulator-produced kV images or digitally reconstructed radiographs 
(as these became available); 1 centre used film. Techniques such as kV planar imaging, cone-beam 
CT, and CT on rails were used by centres in the latter stages of the trial, matching to gold fiducial 
markers or soft tissue (prostate gland). 36 centres used an offline treatment verification procedure, 
imaging the first 3 fractions and then weekly; 5 centres performed daily online verification and 
correction.  
 
Process Document 
Process documents highlighted minor protocol deviations in radiotherapy procedures in 7/41 
centres. Issues were resolved with the centres prior to QA-approval and included: 
 Patients treated with empty bladder (1 centre) 
 No bowel preparation/assessment (4 centres) 
 No patient immobilisation (2 centres) 
 Treatment verification frequency too low (2 centres) 
 Treatment verification tolerance >3mm (7 centres) 
A variety of bladder and bowel preparation techniques were employed, indicating the lack of a 
definitive best practice in these areas. There was a large degree of variation in patient protocols for 
achieving a comfortably full bladder, despite this being standard practice in the majority of UK 
departments [13]. 
Planning benchmark case 
All 41 recruiting radiotherapy centres completed the 2 benchmark cases. 24% (20/82) of plans were 
approved with no variation and 55% (45/82) reported minor variations (unlikely to affect clinical 
outcome). Major variations (with potential to influence clinical outcome, re-plan required) were 
reported in 21% (17/82) of cases. Results are summarised in Table 2, jointly with the case review 
results to enable comparison.  
A difference was noted in the volumes of the PTVs grown by the different TPSs (using identical 
margins) of up to 16% between the smallest (Eclipse) and largest (Pinnacle) PTV volumes. This has 
been investigated and reported in more detail [15]. 
Prospective case reviews 
Clinical outlining  
Prospective individual outlining case reviews were completed for 100 patients from 38 centres (2 
pilot centres exempt and 1 centre’s PI was pre-approved at a different hospital). Results categorised 
as ‘minor variation’ were amended at the discretion of the PI; ‘major variations’ required modifying 
pre-treatment. 
Outlines were approved for 29/100 cases with no variation or minor variations. Major variations 
were identified in 71/100 cases. The frequency of outlining variations (major and minor variations 
combined) per anatomical structure are summarised in Table 3. Figure 2 presents examples of major 
variations in prostate and urethral bulb outlining. 
Treatment Planning 
97 prospective treatment plan reviews were completed for 39 centres (2 pilot centres exempt) and 
the results are summarised in Table 2, using the same classification as the benchmark plans.  
Dosimetry site visit 
Dosimetry site visits were completed for all UK CHHiP centres (except one which only recruited a 
single patient) between 2005-2011. However, data are only available for 32 centres and 39 
treatment plans due to technical problems.  
Ion chamber measurements 
Dose point measurement results are presented as the percentage difference between the measured 
and TPS-calculated dose, and have been normalised to the machine’s daily output.  
All measurements in the high dose prostate PTV region agreed with TPS calculation to within ±2.5% 
(mean 0.6% ± 1.0%).  Measurements were performed in the rectal location for 25/39 plans. Dose 
differences were larger in the rectum, with a maximum difference of +7.9% (mean 1.5% ± 3.4%).  
Measurements of dose in the prostate PTV from individual fields agreed with the TPS-calculated 
dose to within ±5% for all but one centre (5.7% for one field).   
Film measurements 
Film measurements are summarised in Table 4. For individual field fluence maps, the individual 
result with the largest deviation for each plan is shown. Results have been presented in two ways: 
statistics for all plans using 3%/3mm and 4%/4mm gamma parameters; and the number of plans 
achieving various tolerances (Table 1). 
100% of combined field films passed using 4%/4mm gamma criteria and a 95% tolerance (i.e. >95% 
of the analysed film gave a gamma index of <1); 78% passed using more stringent criteria of 
3%/3mm and a 98% tolerance. 73% of fluence maps passed using 4%/4mm gamma parameters and 
a 98% tolerance. 
Feedback questionnaire 
25 centres (61%) completed the feedback questionnaire. Representative quotes from the feedback 
questionnaire are included in Appendix B. 
Patient preparation 
2 centres changed from treating with empty to full bladders. The trial procedures encouraged almost 
half (10/25) of centres to update or formalise their bladder filling requirements. Discussions have 
reinforced the need for better bowel preparation, and 4 centres used CHHiP to pilot the use of rectal 
enemas and dietary advice. 
Clinical outlining 
12/25 centres adapted their prostate and/or rectum outlining as a result of CHHiP. 10/25 stated it 
helped them with audit or consistency of outlining within their department.  
IMRT treatment planning 
10/16 centres using fp-IMRT adopted the technique into routine practice. 7/10 centres using ip-
IMRT used CHHiP to help implement IMRT within their department; 4/10 of these centres rolled out 
IMRT to treat routine prostate patients as a direct result of CHHiP. 
10/25 centres reported benefit from advice given by the CHHiP QA team, primarily with planning 
techniques and optimisation. Additionally, the RTQA physicist co-ordinated networking between 
centres using the same TPS or delivery equipment to resolve equipment-specific issues.  
Dosimetry audit visit 
The consensus was that, while no major errors were discovered, the measurements gave centres 
confidence in their treatment plan delivery, and supplied evidence of peer-assessed external audit. 
Dose constraints 
Most centres used some dose constraints pre-trial, but 12/25 modified their practice to reflect the 
comprehensive set of normal tissue dose constraints specified in the CHHiP trial protocol. 
Implementation of change 
Participation in the CHHiP trial helped develop and accelerate centres’ IMRT programmes, reduced 
resistance to change, and supported quality and evolution of practice and integration into daily 
departmental practice.  
 
Discussion  
Development of IMRT 
An important objective of the CHHiP trial was to help centres implement IMRT. The feedback from 
the post-trial questionnaire indicates that this was achieved, with 7/10 ip-IMRT centres having used 
CHHIP to commission IMRT, and 14/25 centres using CHHIP to roll out ip- or fp-IMRT for routine 
prostate treatment. 
Clinical outlining reviews 
71/100 clinical outlining cases needed amending pre- treatment, and in retrospect a pre-trial 
benchmark outlining case would have been beneficial. There was a progressive reduction in the 
number of centres needing additional reviews for major variations with each review round, although 
the proportion of unsatisfactory outlines changed only slightly. It is possible that major variations 
will have persisted in some centres during the remainder of the trial. The impact of such variation on 
treatment efficacy or toxicity is uncertain but overall trial outcomes were very satisfactory as 
previously reported [1,16].  
In common with other prostate studies [17-20], errors were reported in prostate apex and base 
outlines. This is due to the inherent difficulty of visualising the prostate on CT images, compounded 
by subjective interpretation by different clinicians. Early CHHiP centres used 5mm CT slices so the 
resolution was limiting for outlining. Recent UK prostate radiotherapy trials (PACE [ISRCTN 
17627211], PIVOTALboost [CRUK/16/018]) have recommended a planning MRI scan to help 
delineate the prostate due to its enhanced soft tissue contrast [21], but UK centres currently have 
variable access to MRI resource. 
Urethral bulb outlining was implemented during part II of the trial following RT01 trial analyses [22]. 
However, the urethral bulb is difficult to visualise without MR imaging, despite the provision of a CT-
based outlining atlas, as shown by the large proportion of outlining errors reported (62% of cases). 
18/100 patients reviewed had an inadequately filled bladder, which meant achievement of bladder 
dose constraints was difficult. This highlights the importance of having consistent bladder filling 
instructions for patients, and almost half of centres did formalise their bladder filling procedures as a 
result of the trial. 
Outlining reviews remain an important tool to achieve consistency, and in post-trial feedback 10/25 
of centres reported that the CHHiP QA reviews helped improve consistency of outlining for prostate 
radiotherapy within their department. Pre-trial benchmark outlining cases are now incorporated in 
most UK NIHR-portfolio trials. If resources permit, ongoing outlining QA during trials may also be of 
value. 
Treatment planning QA 
PTV margin growing was the most common source of error for both pre- on on-trial planning QA. 
Results highlighted that the instructions for the complex PTV margins defined in the trial protocol 
needed clarification and these were consequently modified. Margin growing errors can be avoided 
nowadays by implementing automated protocols, although some small differences between TPSs 
will remain. 
Considering both pre- and on-trial plan review results, the proportion of major variations was 
substantially reduced following pre-trial QA from 21% to 6%. Errors of all types were reduced, and in 
particular issues with beam configuration and dose distribution were corrected. The proportion of 
minor variations was similar at both stages; however 10/48 minor variations reported at case review 
were due to missed bladder dose constraints owing to small bladder size. The PAF proved a useful 
tool for quick assessment of plans, and indeed the concept is now being introduced into TPSs. 
The most common treatment planning errors were inadequate conformance of the prescription 
isodoses to their respective PTVs and sub-optimal dose distribution. IMRT was a new technique for 
many centres, and dose distributions for IMRT may differ considerably from 3D conformal 
radiotherapy. Dose conformance requirements are difficult to define in a trial protocol, although use 
of a conformity index [5] could be considered; it is assumed that individual trial centres can produce 
a clinically acceptable dose distribution based on the limitations of their TPS optimiser and delivery 
technique. 
In many cases the 2 benchmark cases were planned and submitted at the same time resulting in 
repetition of errors. It would have been advisable to instruct centres to wait for feedback for their 
first plan before attempting the second case. 
Dosimetry site visit 
At the time of the dosimetry site visits there were no formal recommendations as to suitable 
tolerances for IMRT verification and post-hoc rules were derived from subsequent publications. 
Current criteria are generally stricter since IMRT and the associated planning and delivery systems 
have evolved, and errors in measurement and calculation have reduced. 
PTV dose point results were comparable to those from the PARSPORT head and neck IMRT trial 
dosimetry audit [23]. Measurements in the rectal location were more variable due to the high dose 
gradient and lower dose. The combined plan film results were an improvement over the PARSPORT 
results, possibly due to the complexity of modulation in the head and neck plans compared to 
prostate. 
The results of the dosimetry site visits gave reassurance in the consistency and accuracy of the 
treatment plan delivery for patients in the CHHiP trial. In addition, this was the first IMRT audit for 
many centres and provided external review of their IMRT process.  
The results indicated that there may be potential to scale back the scope of dosimetry site visits for 
future trials. A streamlined ‘postal audit’, using alanine and film, has recently been instigated for UK 
NIHR radiotherapy clinical trials to accredit centres who have previously undertaken a full dosimetry 
audit [24]. The EORTC Radiation Oncology Group are now using “virtual phantom credentialing” [25] 
where measurements are performed on the centre’s own QA phantom and then submitted for 
central analysis. This could generate savings in both time and cost, although the value of such 
credentialing remains controversial [26,27]. 
Feedback questionnaire 
The post-trial feedback questionnaire was novel, and a useful tool to measure the impact of trial QA 
on the on-going delivery of radiotherapy as well as on the trial. The results also confirm the 
importance of radiotherapy trials in improving clinical practice. 
CHHiP OAR dose constraints were adopted as standard by some trial centres, and additionally by 
some non-trial centres after the study closed to recruitment. Several non-trial centres requested 
RTQA support to help implement the CHHiP technique, which is now the standard treatment 
protocol in many UK centres. Treatment planning, delivery and verification procedures mandated by 
the trial protocol encouraged centres to commit resources to commission new techniques, which 
consequently became standard practice. This was aided by support from the CHHiP QA team and 
networking with other trial centres using similar equipment. This helped those centres who had not 
commissioned IMRT overcome technical problems, improve their treatment planning technique, and 
roll out the new technique into clinical practice in a more logical, robust, quicker, and externally 
reviewed manner. 
A QA programme is essential to ensure the consistency and quality of radiotherapy delivery in trials 
using novel radiation techniques. However QA is resource intensive and may delay trial recruitment 
or deter participation. Harmonisation of QA between the various international RTQA groups in order 
to facilitate streamlining of QA in international trials [28] is underway and to be welcomed. 
 
Conclusion 
Implementation of the CHHiP trial has shown how a clinical trial requiring quality-assured high-
technology radiotherapy delivery can benefit the general standard of radiotherapy delivered in 
participating centres by improving consistency, sharing best practice, and supporting the 
implementation of new techniques through a structured radiotherapy QA programme. This in turn 
may improve the quality of the trial data by limiting variation in the radiotherapy treatment 
delivered to trial patients. 
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Appendix A: Normal Tissue Dose Constraints for the CHHiP Trial 
 
Organ Prescribed Dose [Gy] Dose (%) Maximum Volume 
 74Gy/37fr 60Gy/20fr 57Gy/19fr  Optimal Mandatory 
Rectum 30 
40 
50 
60 
65 
70 
74 
24.3 
32.4 
40.5 
48.6 
52.7 
56.8 
60 
23.1 
30.8 
38.5 
46.2 
50.1 
53.9 
57 
41% 
54% 
68% 
81% 
88% 
95% 
100% 
80% 
70% 
- 
- 
- 
- 
- 
- 
- 
60% 
50% 
30% 
15% 
3% 
Bladder 50 
60 
74 
40.5 
48.6 
60 
38.5 
46.2 
57 
68% 
81% 
100% 
 50% 
25% 
5% 
Bowel 50 40.5 38.5 68%  17cc 
Penile bulb 50 
60 
40.5 
48.6 
38.5 
46.2 
68% 
81% 
50% 
10% 
 
Femoral Heads 50 40.5 38.5 68% - 50% 
 
Table A.1. Normal tissue dose constraints for the CHHiP trial 
  
Appendix B: CHHiP Feedback Questionnaire and Results 
This appendix reports quotes from the CHHiP Feedback Questionnaire, sent to centres after the trial 
closed, on changes to their local prostate radiotherapy procedures directly resulting from 
participation in the CHHiP trial. 
Patient preparation 
Advice to patients regarding bladder filling 
“Prior to CHHiP empty bladder instructions were given, but once CHHiP opened this was changed to 
comfortably full bladder for all patients across the department.” 
“Implementation of a bladder filling protocol as department standard for all prostate patients. 
Incorporated into patient information leaflets.” 
“At CT planning scan stage, control slices (1-2 slices) were introduced to check rectal/bladder filling 
before performing prostate scan.” 
Procedures regarding rectal filling 
“Micro-enemas were initially introduced for CHHiP trial patients only. Then clinicians implemented 
this for all prostate patients.” 
“Positive impact. We now have robust protocols in place, partly as a result of CHHIP trial influence.” 
“We introduced re-scans about 5 years ago, and rectal enemas about two years ago. Not directly 
due to CHHiP, but the regularity of the teleconferences and general awareness of the issues was 
repetitively drummed home!” 
Clinical outlining 
Procedures for outlining prostate, seminal vesicles, urethral bulb, rectum 
“We now outline as per CHHiP protocol for all low and medium risk patients having radiotherapy to 
prostate. Previously outlining was variable (most used ProtecT trial protocol).” 
“Improvement with regard to prostate apex, membranous urethra, and urethral bulb.” 
“Urethral bulb not normally outlined. Due to the difficulty of outlining, we probably won’t continue 
in normal practise.” 
Clinical audit and consistency of clinical outlining within the department 
“The CHHIP outlining exercise has been the principal training and audit mechanism.” 
“Established with clinicians that contouring OAR should be standard practice.” 
“It has helped to get agreement between consultants with regard to outlining, dose, tolerances, etc., 
and also hormone therapy.” 
“The review process has proved a very useful tool, and one which we would be keen to participate in 
again should the opportunity arise.  Certainly it has sparked debate within our centre and reinforced 
the need for a clinical audit to measure consistency.” 
Radiotherapy treatment planning 
Forward-planned IMRT 
Changes in forward-planning technique, e.g. beam arrangements 
“Our forward-planned IMRT was developed through CHHIP, and extended to our standard 
departmental prostate planning protocols.” 
“Previously we treated patients with anterior, left and right posterior oblique beams. Now all 
prostate patients are treated with anterior, left and right lateral beams.” 
“Radiographers like having a single plan rather than phase 1 and phase 2. CHHiP segmented plans 
helped to introduce the concept of segments and control points to treatment radiographers.” 
“Introducing CHHiP using segmented techniques helped everyone to be less fearful of full-blown 
inverse-planned IMRT.” 
Inverse-planned IMRT 
Did you use CHHiP to help implement IMRT within your department? 
“CHHiP was used to implement IMRT in our department; and the CHHiP patients were our first IMRT 
patients.” 
“CHHiP was used as the basis for developing our IMRT programme.” 
“We used the CHHiP patients to develop our IMRT patient QA methodology.” 
“Useful way of increasing IMRT numbers in a safe/controlled way.” 
Are you planning your routine prostate patients using IMRT as a result of CHHiP? 
“CHHiP trial helped us to introduce IMRT for prostate patients in a very controlled and confident 
manner. “ 
“We changed to inverse-planning part-way through the trial. After we had gained experience with 
the technique and confidence with the per-patient QA/delivery, the technique was adapted for 
routine prostate radiotherapy and all our prostates are now treated with IMRT.” 
What help did you receive with IMRT from the CHHiP team? 
“The intellectual gain for the department with respect to planning and QA of IMRT technique is very 
significant and we are very grateful for it.” 
“We used the beam selection from the Clatterbridge CHHiP protocol. They suggested extra volumes 
as outlined in the Royal Marsden protocol, following failure in the planning exercise, which was 
invaluable even though it used the Eclipse planning system.” 
“Decided to use segmented forward-planned CHHiP technique provided by Royal Marsden (Sutton).” 
“Put in touch with another centre using the same TPS, which helped during development of the 
planning process.  Feedback from planning exercises was also helpful in refining the planning 
process.” 
“Networking with other Elekta and OMP users.” 
Dosimetry audit 
How did the dosimetry audit visit help you? 
“Useful as a pre-implementation check for inverse-planned IMRT.” 
“It gave us confidence in the dosimetry of our set-up.” 
“Gave reassurance, and we were able to do our own film dosimetry and compare with audit. Report 
gave useful information for future gamma analysis for film dosimetry.” 
Dose constraints 
“As a result of participating in the CHHiP trial, we have adopted the normal tissue constraints and 
applied them to all of our prostate patients.” 
“We now use the CHHiP dose constraints for the rectum and bladder (previously no constraints for 
OARs).” 
“No, in fact the constraints are ‘lighter’ in the trial, e.g. our V60Gy is 35%.” 
“Enabled the adoption of 74Gy as standard prescription.“ 
Treatment verification 
“As a result of the CHHiP trial, we are now routinely acquiring portal images for the first 3 fractions 
and weekly thereafter for all radical treatments. This has required changes to protocol and 
development of appropriate documentation to support these changes.” 
“Our tolerance levels were not as tight as CHHiP’s originally for imaging, but we have now brought 
down the acceptable margins to CHHiP levels for all our patients having prostate radiotherapy.” 
Departmental and staff development 
Have the requirements for the CHHiP trial helped to implement changes within the department? 
“Our radiotherapy staff are now enthused to continue to develop a routine IMRT service. The 
experience has also highlighted to the management in the Trust the ability of the department to 
implement change of this type.” 
“The usual ‘resistance to change’ was met with hard deadlines that had to be met due to 
participation in a trial. This obviously raised the priority of CHHiP above other clinical developments 
and bypassed the usual politics involved in introducing a new technique.” 
“The trial helped with: general departmental enthusiasm; involvement of research nursing staff in 
radiotherapy trials rather than medical oncology trials; other staff groups’ and members’ 
involvement in research trials; confidence in the introduction of different techniques in a controlled 
manner.” 
“For the staff that have been involved it has been beneficial, increasing their experience, expertise 
and, to some extent, their confidence.” 
“Research radiographers are doing prostate trial (not only CHHiP) patients’ follow-ups in clinics 
personally; this was not the case at the beginning of the trial. This has made an impact on the 
workload of the consultant teams as they no longer follow up these patients themselves unless they 
develop recurrence, and has led to role development for the research radiographers.” 
“The control arm of clinical trial protocols can provide useful information for smaller departments 
when updating techniques.” 
Radiotherapy trial participation 
“It has played a major part in getting our radiotherapy trials team up and running.” 
“As the CHHiP trial was a large radiotherapy trial, along with the IMPORT trial it helped promote 
radiotherapy trials in our department and this is an area we are continuing to promote and 
encourage.” 
“As a centre we had quite a low level of recruitment to radiotherapy clinical trials before going live 
with CHHiP. CHHiP alone in 2010 has provided us with almost the same amount of total recruitment 
as to all radiotherapy clinical trials in 2009.  It is our largest recruiting study this year, and has helped 
show that large-scale recruitment is possible.” 
 
 
Figure 1. PTV margins and doses for the CHHiP trial. In patients with a low risk [4] of seminal vesicle 
(SV) involvement the base of SV (proximal 2cm) was included, those with moderate or high risk had 
all of SV included. 
  
  
 
Figure 2. Measurement of (a, top) dose to PTV and rectum using ion chamber and, (b, bottom) full 
plan delivery to axial film for a CHHiP ip-IMRT plan in the CIRS pelvic phantom.
     
 
Figure 2. Examples of major variations in outlining the prostate target volume and the urethral bulb. 
In Figures 2a and b (top left and right) the prostate apex has been inadequately outlined. In 2a 
prostate outlines did not encompass the whole gland posteriorly (centre outlines are yellow, review 
outlines purple); in 2b outlines were generally too small (centre outlines blue, review outlines red). 
Figure 2c shows 3 consecutive axial views of urethral bulb outlining and 1 sagittal view (right); centre 
outlines are cyan, review outlines purple.  
  
 Source of data IPEM Report 96 [9] Budgell et al [10] Royal Marsden 
Hospital (RMH) *  
EqualESTRO and 
IROC audits [11,12] 
Example clinical tolerances for point doses 
Individual beam 
tolerance 
3% 3% 5%  
Total dose tolerance 2% 2% 3% 5% 
Critical organ tolerance 
(rectum, total dose) 
2%    
Example clinical tolerances for combined dose distributions 
Dose/DTA criterion 3% / 3mm 
 
3% / 3mm 4% / 4mm  
Tolerance 98% of pixels inside 
80% isodose 
98% of pixels inside 
80% isodose 
95% (no lower dose 
threshold) 
 
Example clinical tolerances for fluence maps 
Dose/DTA criterion and 
dose threshold 
4% / 4mm    
Tolerance 98% of pixels inside 
20% isodose 
   
* Using knowledge from process used at RMH 
Table 1. Literature-derived clinical tolerances for patient QA measurements for IMRT prostate plans 
  
 Variation type Pre-trial benchmark case On-trial prospective case 
review 
 Major 
variation 
Minor 
variation 
Major 
variation 
Minor 
variation 
PTV margin growing error 11 (13%) 32 (39%) 14 (14%) 20 (21%) 
Inadequate conformance of 
high dose to PTV 
11 (13%) 25 (30%) 2 (2%) 24 (25%) 
Inadequate dose coverage of 
PTVs 
3 (4%) 6 (7%) 2 (2%) 9 (9%) 
Dose distribution sub-optimal 5 (6%) 1 (1%) 0 0 
Hotspots in dose distribution 5 (6%) 9 (11%) 2 (2%) 3 (3%) 
Dose constraints missed 7 (9%) 15 (18%) 2 (2%) 29 (30%) † 
Beam configuration sub-
optimal # 
1 (1%) 8 (10%) 0 0 
Plan assessment form 
completion errors 
n/a 47 (57%) n/a 29 (30%) 
Patient data not anonymised n/a n/a n/a 6 (6%) 
Overall plan review result * 82 cases  97 cases  
No variation 20 (24%)  43 (44%)  
Minor variation 45 (55%)  48 (49%) †  
Major variation 17 (21%)  6 (6%)  
# A beam configuration of 3 orthogonal fields was recommended for fp-IMRT [14] and 5 fields for ip-
IMRT. 
* PTV margin errors were not included in the overall plan review result as these were considered 
outlining errors; however PTV margins were assessed during treatment plan review. 
† 10/48 minor variations were solely due to missed bladder dose constraints owing to inadequate 
bladder filling 
Table 2. Treatment planning results for pre- and on-trial QA for CHHiP 
  
  No. occurrences Breakdown by review number 
Outlining variation 100 cases 1st Review 
(38 cases) 
2nd Review 
(37 cases) 
3rd Review 
(21 cases) 
4th Review 
(3 cases) 
Location of prostate 
apex 
44% (44) 42% (16) 51% (19) 38% (8) 33% (1) 
Location of prostate 
base 
29% (29) 29% (11) 32% (12) 19% (4) 67% (2) 
Other prostate outlining 13% (13) 11% (4) 14% (5) 14% (3) 33% (1) 
Seminal vesicle 
outlining 
39% (39) 50% (19) 30% (11) 38% (8) 33% (1) 
Location of recto-
sigmoid junction 
43% (43) 50% (19) 38% (14) 48% (10) 0% (0) 
Rectum inferior 
endpoint 
32% (32) 37% (14) 30% (11) 33% (7) 0% (0) 
Large rectal distension 4% (4) 5% (2) 0% (0) 10% (2) 0% (0) 
Bowel not adequately 
outlined 
38% (38) 55% (21) 24% (9) 33% (7) 33% (1) 
Inadequate bladder 
filling 
18% (18) 24% (9) 11% (4) 24% (5) 0% (0) 
Bladder outlining 9% (9) 13% (5) 5% (2) 10% (2) 0% (0) 
Femoral head outlines 
(included femoral neck) 
28% (28) 34% (13) 22% (8) 33% (7) 0% (0) 
Urethral bulb outlining 
* 
62% (50/81) 68% 
(21/31) 
50% 
(15/30) 
76% 
(13/17) 
33% (1/3) 
Overall review result      
Approved 5% (5) 0% (0) 11% (4) 0% (0) 0% (0) 
Minor variation 24% (24) 21% (8) 16% (6) 43% (9) 33% (1) 
Major variation 71% (71) 79% (30) 73% (27) 57% (12) 67% (2) 
* Urethral bulb outlining was introduced mid-trial; earlier plans did not outline the bulb 
Table 3. Outlining QA results for CHHiP prospective case reviews 
 
 Combined plan results (36 plans) Individual field (fluence map) results 
(15 plans) 
Gamma 
parameters 
3%/3mm 4%/4mm 3%/3mm 4%/4mm 
% pixels with γ<1 98.9% ± 1.7% 99.7% ± 0.9% 94.6% ± 6.8% 97.5% ± 4.5% 
% films passing, 
using a threshold 
of: 
    
>98% pixels γ<1  78% (28/36) 97% (35/36) 33% (5/15) 73% (11/15) 
>95% pixels γ<1 97% (35/36) 100% (36/36) 73% (11/15) 87% (13/15) 
 
Table 4. Film results for CHHiP dosimetry audits, evaluated using gamma analysis 
 
  
 
 
 
